Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ana Velez

Infectious Disease Tampa, FL Medical Doctor

NPI 1063589695 CMS profile 320985

2 Tampa General Cir, Tampa, FL 33606

Open in the dashboard

General payments

$132

4 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Velez of Tampa, FL is reported in the CMS Open Payments database as having received $132 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103 2
2024 General $15 1
2022 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Velez
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Ana Velez were reported at $103. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Ana Velez Infectious Disease median Middle half National median
2019 $0 $190 $60–$862 $163
2020 $0 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $14 $166 $50–$834 $149
2023 $0 $171 $57–$787 $160
2024 $15 $176 $52–$752 $164
2025 $103 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. CorMedix Inc. $74 1 payment
  2. Cala Health, Inc. $29 1 payment
  3. Nevro Corp. $15 1 payment
  4. Boston Scientific Corporation $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $132 4 payments
Products named General payments · program years 2022–2025
  1. DefenCath $74 1 payment
  2. Cala kIQ $29 1 payment
  3. Senza $15 1 payment
  4. WATCHMAN Access System $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

87

Median for Infectious Disease: 268

Drug cost

$126,820

Median for Infectious Disease: $217,595

Branded share of claims

67.8%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 24 $92,785
Isentress Raltegravir Potassium Brand 12 $26,947
Tigecycline Generic 15 $6,319
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $353
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $234
Acyclovir Generic 13 $181

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$36,116

Medicare's payments for the services billed

Medicare patients

208

Average age 72

Services billed

536

80 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Cancer 46%
Ischemic heart disease 45%
Chronic kidney disease 42%
COPD 39%
Diabetes 38%
Heart failure 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record